Literature DB >> 23021722

Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.

C William Helm1.   

Abstract

Epithelial ovarian cancer is a peritoneal surface malignancy that most often presents with spread of disease within the peritoneal cavity. Overall 5-year survival is around 50% and progress in improving outcomes is slow. Among other areas of research, hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising option. This article reviews the current status of treatment of epithelial ovarian cancer, experience with HIPEC to date, and future directions.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23021722     DOI： 10.1016/j.soc.2012.07.007

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  11 in total

Review 1.  Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.

Authors:  Renee A Cowan; Roisin E O'Cearbhaill; Oliver Zivanovic; Dennis S Chi
Journal:  Int J Hyperthermia       Date:  2017-08       Impact factor: 3.914

Review 2.  Management of recurrent epithelial ovarian cancer.

Authors:  Víctor Manuel Vargas-Hernández; Mario Adan Moreno-Eutimio; Gustavo Acosta-Altamirano; Víctor Manuel Vargas-Aguilar
Journal:  Gland Surg       Date:  2014-08

Review 3.  Peritoneal carcinomatosis.

Authors:  Federico Coccolini; Federico Gheza; Marco Lotti; Salvatore Virzì; Domenico Iusco; Claudio Ghermandi; Rita Melotti; Gianluca Baiocchi; Stefano Maria Giulini; Luca Ansaloni; Fausto Catena
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

4.  Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.

Authors:  Yao An Shen; Ing Luen Shyu; Maggie Lu; Chun Lin He; Yen Mei Hsu; Hsiang Fa Liang; Chih Peng Liu; Ren Shyan Liu; Biing Jiun Shen; Yau Huei Wei; Chi Mu Chuang
Journal:  Int J Nanomedicine       Date:  2015-03-30

5.  Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.

Authors:  Angelo Di Giorgio; Pierandrea De Iaco; Michele De Simone; Alfredo Garofalo; Giovanni Scambia; Antonio Daniele Pinna; Giorgio Maria Verdecchia; Luca Ansaloni; Antonio Macrì; Paolo Cappellini; Valerio Ceriani; Giorgio Giorda; Daniele Biacchi; Marco Vaira; Mario Valle; Paolo Sammartino
Journal:  Ann Surg Oncol       Date:  2016-11-28       Impact factor: 5.344

6.  Cytoreduction surgery and hyperthermic intraperitoneal chemotherapy for treating advanced peritoneal metastases of hepatocellular carcinoma.

Authors:  Kuo-Chen Hung; Kun-Lin Yang; Guan-Cheng Huang; Yu-Fu Chen; Wen-Teng Chang; Chia-Chang Chuang
Journal:  Pleura Peritoneum       Date:  2020-05-15

7.  Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.

Authors:  Xiaoli He; Li Wei; Rui Li; Shuang Jing; Linlin Jia; Danwei Ji; Yali Li; Yue Wang; Yongxia Zhu
Journal:  BMC Cancer       Date:  2021-06-27       Impact factor: 4.430

8.  Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer.

Authors:  Ting Zhang; Qiong Pan; Songshu Xiao; Lijie Li; Min Xue
Journal:  Oncol Lett       Date:  2016-04-05       Impact factor: 2.967

9.  Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma.

Authors:  Xiaoping Song; Kailv Sun; Jianming Hu; Jianghu Zhou
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

10.  Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis.

Authors:  Maurizio Cardi; Paolo Sammartino; Valentina Mingarelli; Simone Sibio; Fabio Accarpio; Daniele Biacchi; Daniela Musio; Bianca Sollazzo; Angelo Di Giorgio
Journal:  World J Surg Oncol       Date:  2015-10-22       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.